---
layout: post
title: "Laser-Assisted In Situ Keratomileusis Lasers-Patient Labeling Recommendations; Draft Guidance for Industry and Food and Drug Administration Staff; Availability; Extension of Comment Period"
date: 2026-02-05 19:01:04 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-21971
original_published: 2022-10-11 00:00:00 +0000
significance: 8.00
---

# Laser-Assisted In Situ Keratomileusis Lasers-Patient Labeling Recommendations; Draft Guidance for Industry and Food and Drug Administration Staff; Availability; Extension of Comment Period

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** October 11, 2022 00:00 UTC
**Document Number:** 2022-21971

## Summary

The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice of availability that appeared in the Federal Register of July 28, 2022. In the notice of availability, FDA requested comments on draft guidance for industry and FDA staff entitled "Laser-Assisted In Situ Keratomileusis (LASIK) Lasers--Patient Labeling Recommendations." The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/10/11/2022-21971/laser-assisted-in-situ-keratomileusis-lasers-patient-labeling-recommendations-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2022-21971

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
